These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of tocainide enantiomers on experimental arrhythmias produced by programmed electrical stimulation. Uprichard AC; Allen JD; Harron DW J Cardiovasc Pharmacol; 1988 Feb; 11(2):235-41. PubMed ID: 2452320 [TBL] [Abstract][Full Text] [Related]
3. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model. Uprichard AC; Harron DW Br J Pharmacol; 1989 Jan; 96(1):220-6. PubMed ID: 2924074 [TBL] [Abstract][Full Text] [Related]
4. Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. Chézalviel F; Weissenburger J; Guhennec C; Jagueux M; Davy JM; Vernhet L; Simandoux V; Poirier JM; Cheymol G J Cardiovasc Pharmacol; 1993 Feb; 21(2):212-20. PubMed ID: 7679154 [TBL] [Abstract][Full Text] [Related]
5. Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of mexiletine in patients with ventricular tachycardia. Kim SG; Seiden SW; Matos JA; Waspe LE; Fisher JD Am Heart J; 1986 Jul; 112(1):14-9. PubMed ID: 3728269 [TBL] [Abstract][Full Text] [Related]
6. Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing. DiMarco JP; Garan H; Ruskin JN Am J Cardiol; 1981 Jan; 47(1):131-8. PubMed ID: 7457398 [TBL] [Abstract][Full Text] [Related]
7. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Waleffe A; Mary-Rabine L; Legrand V; Demoulin JC; Kulbertus HE Am Heart J; 1980 Dec; 100(6 Pt 1):788-93. PubMed ID: 7446381 [TBL] [Abstract][Full Text] [Related]
8. Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients. Waspe LE; Waxman HL; Buxton AE; Josephson ME Am J Cardiol; 1983 Apr; 51(7):1175-81. PubMed ID: 6340451 [TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation. Kim SG; Felder SD; Waspe LE; Fisher JD Am J Cardiol; 1986 Sep; 58(6):485-90. PubMed ID: 3529910 [TBL] [Abstract][Full Text] [Related]
10. Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. Duff HJ; Mitchell LB; Manyari D; Wyse DG J Am Coll Cardiol; 1987 Nov; 10(5):1149-56. PubMed ID: 3668109 [TBL] [Abstract][Full Text] [Related]
11. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874 [TBL] [Abstract][Full Text] [Related]
12. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. Yeung-Lai-Wah JA; Murdock CJ; Boone J; Kerr CR J Am Coll Cardiol; 1992 Sep; 20(3):547-51. PubMed ID: 1512331 [TBL] [Abstract][Full Text] [Related]
13. Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers. Banitt EH; Schmid JR; Newmark RA J Med Chem; 1986 Feb; 29(2):299-302. PubMed ID: 3950909 [TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. Control by programmed ventricular stimulation. Manz M; Steinbeck G; Nitsch J; Lüderitz B Br Heart J; 1983 Mar; 49(3):222-8. PubMed ID: 6830659 [TBL] [Abstract][Full Text] [Related]
15. Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies. Flaker GC; Madigan NP; Alpert MA; Moser SA Am Heart J; 1984 Sep; 108(3 Pt 1):490-5. PubMed ID: 6475711 [TBL] [Abstract][Full Text] [Related]
16. Mexiletine's antifibrillatory actions are limited by the occurrence of convulsions in conscious animals. Igwemezie LN; Beatch GN; McErlane KM; Walker MJ Eur J Pharmacol; 1992 Jan; 210(3):271-7. PubMed ID: 1612103 [TBL] [Abstract][Full Text] [Related]
17. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Monk JP; Brogden RN Drugs; 1990 Sep; 40(3):374-411. PubMed ID: 2226221 [TBL] [Abstract][Full Text] [Related]
19. Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias. Poole JE; Werner JA; Bardy GH; Graham EL; Pulaski WP; Fahrenbruch CE; Greene HL Am Heart J; 1986 Aug; 112(2):322-6. PubMed ID: 3739884 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of oral quinidine-mexiletine combination therapy for sustained ventricular tachyarrhythmias as assessed by programmed electrical stimulation when quinidine monotherapy has failed. Bonavita GJ; Pires LA; Wagshal AB; Cuello C; Mittleman RS; Greene TO; Huang SK Am Heart J; 1994 Apr; 127(4 Pt 1):847-51. PubMed ID: 8154423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]